These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 24078773)

  • 1. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.
    Jahchan NS; Dudley JT; Mazur PK; Flores N; Yang D; Palmerton A; Zmoos AF; Vaka D; Tran KQ; Zhou M; Krasinska K; Riess JW; Neal JW; Khatri P; Park KS; Butte AJ; Sage J
    Cancer Discov; 2013 Dec; 3(12):1364-77. PubMed ID: 24078773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teaching an old dog new tricks: drug repositioning in small cell lung cancer.
    Wang J; Byers LA
    Cancer Discov; 2013 Dec; 3(12):1333-5. PubMed ID: 24327694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth.
    Johnson SS; Liu D; Ewald JT; Robles-Planells C; Pulliam C; Christensen KA; Bayanbold K; Wels BR; Solst SR; O'Dorisio MS; Menda Y; Spitz DR; Fath MA
    Cancer Biol Ther; 2024 Dec; 25(1):2382524. PubMed ID: 39054566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
    Kawabata S; Connis N; Gills JJ; Hann CL; Dennis PA
    Anticancer Res; 2021 Jan; 41(1):91-99. PubMed ID: 33419802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
    Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
    Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
    Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
    Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
    Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
    Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
    [No Abstract]   [Full Text] [Related]  

  • 8. Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells.
    Pettersson HM; Pietras A; Munksgaard Persson M; Karlsson J; Johansson L; Shoshan MC; Påhlman S
    Mol Cancer Ther; 2009 Jan; 8(1):160-70. PubMed ID: 19139125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Inhibition of the E3 Ligase SCF
    Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
    Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.
    Riess JW; Jahchan NS; Das M; Zach Koontz M; Kunz PL; Wakelee HA; Schatzberg A; Sage J; Neal JW
    Cancer Treat Res Commun; 2020 Apr; 23():100174. PubMed ID: 32413603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H446 and H1688 human small-cell lung cancer cells.
    Fang C; Zhang J; Qi D; Fan X; Luo J; Liu L; Tan Q
    PLoS One; 2014; 9(12):e115204. PubMed ID: 25506932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
    Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
    Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of degradable niclosamide derivatives able to specially inhibit small cell lung cancer (SCLC).
    He X; Li M; Ye W; Zhou W
    Bioorg Chem; 2021 Feb; 107():104574. PubMed ID: 33383327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer.
    Whalen KA; White BH; Quinn JM; Kriksciukaite K; Alargova R; Au Yeung TP; Bazinet P; Brockman A; DuPont MM; Oller H; Gifford J; Lemelin CA; Lim Soo P; Perino S; Moreau B; Sharma G; Shinde R; Sweryda-Krawiec B; Bilodeau MT; Wooster R
    Mol Cancer Ther; 2019 Nov; 18(11):1926-1936. PubMed ID: 31649014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
    Akeno N; Reece AL; Callahan M; Miller AL; Kim RG; He D; Lane A; Moulton JS; Wikenheiser-Brokamp KA
    Mol Cancer Ther; 2017 Dec; 16(12):2913-2926. PubMed ID: 28847987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
    Saunders LR; Bankovich AJ; Anderson WC; Aujay MA; Bheddah S; Black K; Desai R; Escarpe PA; Hampl J; Laysang A; Liu D; Lopez-Molina J; Milton M; Park A; Pysz MA; Shao H; Slingerland B; Torgov M; Williams SA; Foord O; Howard P; Jassem J; Badzio A; Czapiewski P; Harpole DH; Dowlati A; Massion PP; Travis WD; Pietanza MC; Poirier JT; Rudin CM; Stull RA; Dylla SJ
    Sci Transl Med; 2015 Aug; 7(302):302ra136. PubMed ID: 26311731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer.
    Liu X; Wang W; Yin Y; Li M; Li H; Xiang H; Xu A; Mei X; Hong B; Lin W
    Invest New Drugs; 2019 Dec; 37(6):1166-1176. PubMed ID: 30825105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.